Moderate

Retinopathy of prematurity (ROP) — screening & referral

Screen <=31 wk or <=1500 g · Paediatric
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

ROP is a vasoproliferative retinal disorder of preterm infants that can progress to retinal detachment and blindness but is highly treatable if detected in time. Structured screening of at-risk babies and prompt treatment of threshold/type 1 disease prevent avoidable visual loss.

Red flags

  • Plus disease (dilated, tortuous posterior retinal vessels)
  • Zone I disease or aggressive posterior ROP
  • Rapid progression between examinations
  • Any eligible infant not yet screened
  • Treatment not delivered within the recommended window

Assessment

Differential diagnosis

  • Retinopathy of prematurity (staged 1-5, with plus disease)
  • Familial exudative vitreoretinopathy
  • Persistent fetal vasculature
  • Congenital retinal vascular anomalies
  • Incontinentia pigmenti (retinal involvement)

Investigations

  • Dilated indirect ophthalmoscopy by a trained ophthalmologist (or validated retinal imaging/telemedicine)
  • Staging of ROP (zone, stage, presence of plus disease)
  • Documentation of zone I/II/III and aggressive posterior ROP
  • Serial examinations until retinal vascularisation is complete/low-risk
  • Record gestational age and birth weight to confirm screening eligibility

Management

  • Identify eligible infants: in the UK, all babies born <31 weeks' gestation OR <1501 g birth weight (criteria vary by country; AAP uses <=30 weeks or <=1500 g plus selected sicker larger infants)
  • Time the first examination by postmenstrual/postnatal age: for babies born <27 weeks screen at 30-31 weeks PMA; for 27-32 weeks screen at 4-5 weeks postnatal age
  • Dilate pupils with appropriate mydriatic drops before examination and provide comfort measures
  • Have an experienced ophthalmologist examine and stage both eyes using indirect ophthalmoscopy or imaging
  • Record zone, stage and plus disease clearly in the notes
  • Continue screening at intervals (usually 1-2 weekly) determined by findings until the retina is fully vascularised or risk has passed
  • Treat type 1 / threshold ROP promptly — ideally within 48-72 hours — with laser photocoagulation or intravitreal anti-VEGF
  • Minimise and target supplemental oxygen to reduce ROP risk while avoiding hypoxia
  • Ensure no eligible baby is discharged or transferred without screening handover arranged
  • Arrange ophthalmology follow-up after treatment and long-term vision/refraction surveillance

Drugs & doses

Mydriatic eye drops (e.g. cyclopentadiolate 0.5% + phenylephrine 2.5%) before examination
Topical anaesthetic drops and sucrose/comfort measures during examination
Intravitreal anti-VEGF (e.g. bevacizumab or ranibizumab) for type 1 ROP where indicated
Laser photocoagulation as treatment for type 1 / threshold disease

Disposition

Ophthalmology-led screening programme on the neonatal unit; urgent treatment for type 1 disease. Mandatory follow-up after discharge for continued retinal and refractive surveillance.

Complications & pitfalls

  • Retinal detachment and blindness
  • Myopia, strabismus and amblyopia
  • Recurrence after anti-VEGF requiring re-treatment
  • Systemic anti-VEGF exposure concerns
  • Late retinal detachment in adolescence/adulthood

Exam pearls

  • ROP screening is time-critical — the treatment window for sight-threatening disease is narrow
  • Avoid both hyperoxia and large oxygen swings; target saturation ranges per unit policy
  • Plus disease is the key sign driving treatment, more than stage alone
  • Never let an eligible baby leave the service without screening arrangements confirmed

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.